Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerTyrosine Kinase Inhibitors for the ElderlyFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceS-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.EGFR: The Paradigm of an Oncogene-Driven Lung CancerNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibPredictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.[Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].244-MPT overcomes gefitinib resistance in non-small cell lung cancer cellsCranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastasesClinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.Geographic Variations and Time Trends in Cancer Treatments in TaiwanMechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.Safety of gefitinib in non-small cell lung cancer treatment.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.The anticipated next season of EGFR inhibitors.Evaluation of the relevance of surgery in a retrospective case series of patients who underwent the surgical treatment of a symptomatic spine metastasis from lung cancer.Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.EGFR tyrosine kinase inhibitors differentially affect autophagy in head and neck squamous cell carcinoma.Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma.Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.[Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A Meta-analysis].The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer.PATRI, a Genomics Data Integration Tool for Biomarker Discovery
P2860
Q26740529-818857A8-5570-4FD0-BB43-AAF79251D9D1Q26748567-8E9C441B-9F6E-4EB3-A7F0-F685642AC530Q28077347-9E5D0684-77E4-4261-B5D1-985BBF22B3A8Q33426501-3CA6C073-7AB0-4D7C-BD6A-ADACA878970EQ33437650-4EDB6E39-019D-4A59-94C1-07D0A08D93E8Q33662730-7447705C-0E4F-4615-86B4-08922B038C0AQ33686369-DF566154-FBED-4D8F-A9CB-89C6767236C7Q33807542-B914F4C1-F85C-452A-A04C-D648F9D3E958Q35619241-E2982EC9-2299-4F0A-A826-C3E2925F1B51Q35807946-BEA04725-B038-4CD2-80AC-D8213BC14AE8Q35824117-07D92C59-4ECB-49D2-BA0D-ADE0ABBE626DQ36225679-1DE27583-AC24-48F4-9C97-3A7FFE69199BQ36688956-D97AD836-09E9-4753-870C-A15DD5AA57BCQ38549746-15442C6B-1D79-4FAA-82F3-F39D98C28B14Q38641499-8C750711-75E1-4C43-97BC-1BDB1FB951EEQ38646251-CC222DA2-D376-4E71-BC16-2AE635D3F013Q38758979-57B834A4-DE41-43C7-A49B-83D12D635608Q38841473-A4F51AE6-C59D-47D5-B73E-A3FB15EAEE1FQ38948950-0BD937B9-9790-40BE-9E88-7254019E50EBQ38989374-5A2ED9A0-2D6D-4495-8F3A-AEE4FBAD3C53Q39458466-3AC93090-BDD5-4CEB-9D48-FDFD0F2392A3Q40048096-0FA827DC-EF11-4FAC-BD30-AA7B0D413B3FQ40535967-878B3766-DB27-4F70-96D3-AA955B9F84DBQ45056156-ABE8EFD7-DAB8-4BDF-8C1A-077A058ADB65Q47253056-0A7EBCFA-BD79-4C60-B715-D00373A549A1Q48029549-1EA8863A-F2D2-4254-A190-BBA7C21DE490Q49582579-0F594794-8B37-46C0-A821-06C3E2003CBCQ49887903-184B5DCE-FB92-4590-BBC8-9B446FF5C9E1Q50133191-7F214A55-CEA7-4203-98AA-C2CD36F2660CQ51743342-E05F228C-F9F3-4314-B99E-315632F82322Q52591096-FA4C6D4A-9116-43EB-AB85-81D8828D9DCCQ53394177-77C68E96-270A-4A2B-BCE0-292BB6EA634DQ54166640-2D229369-BC1A-48C4-ABA5-EE3C47AF7FABQ54219751-6752B33E-A2E2-4E42-9814-6B9D9A75BDFBQ54982443-09DE1D58-2A3A-4C3D-8FD1-08E4EA7C930AQ55030214-6A19840C-F852-45B3-BCB1-282D1917AC50Q55230293-86F6F64E-E647-4568-8AF5-4F407B37D6A2Q58883545-B36D5B9C-9E57-46D9-B127-74ED56654DD5
P2860
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Gefitinib and erlotinib in met ...... of randomized clinical trials.
@ast
Gefitinib and erlotinib in met ...... of randomized clinical trials.
@en
type
label
Gefitinib and erlotinib in met ...... of randomized clinical trials.
@ast
Gefitinib and erlotinib in met ...... of randomized clinical trials.
@en
prefLabel
Gefitinib and erlotinib in met ...... of randomized clinical trials.
@ast
Gefitinib and erlotinib in met ...... of randomized clinical trials.
@en
P2093
P2860
P1433
P1476
Gefitinib and erlotinib in met ...... of randomized clinical trials
@en
P2093
Elisabet E Manasanch
Mauricio Burotto
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0154
P577
2015-03-20T00:00:00Z